Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
iGlarLixi improves glycaemic control in adults with T2D.
Last updated September 12, 2026
Key finding
HbA1c reductions were greater with iGlarLixi versus IDegAsp.
The study evaluated iGlarLixi's effectiveness in improving glycaemic control in Chinese adults with T2D compared to IDegAsp, showing better outcomes with lower insulin doses.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated iGlarLixi's effectiveness in improving glycaemic control in Chinese adults with T2D compared to IDegAsp, showing better outcomes with lower insulin doses.
Clinical relevance
These findings are significant as they suggest that iGlarLixi may offer a safer and more effective treatment option for managing blood sugar levels in adults with type 2 diabetes, particularly in populations where hypoglycaemia is a concern. Improved glycaemic control with lower insulin doses can enhance patient adherence and overall health outcomes.
Keep in mind
The study's effectiveness data were classified as unclear. Limited generalizability due to the specific population studied. Potential for unmeasured confounders affecting outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Saichun Z, Yunjuan G, Yu C, et al. iGlarLixi provides improved glycaemic control at lower insulin doses with reduced risk of hypoglycaemia in Chinese adults with suboptimally controlled T2D. Diabetes, Obesity & Metabolism. 2026;28(10):9091-9100. doi:10.1111/dom.71057
Main Effects
iGlarLixi demonstrated a greater HbA1c reduction of -0.59 percentage compared to IDegAsp.
Total insulin daily doses were lower with iGlarLixi, showing a decrease of -3.34 units/day.
Hypoglycaemia event rates were consistently lower with iGlarLixi compared to IDegAsp.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin aspart, Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Hypoglycemia events, Reduction in HbA1c levels in MASH responders, Total daily insulin dose.
This study contributes evidence to
Primary intervention
Insulin aspart
Primary outcomes
- Hypoglycemia events
- Reduction in HbA1c levels in MASH responders
- Total daily insulin dose
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
6
Evidence pairs
779
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Insulin Therapies and Insulin Resistance
Related evidence
Evidence relationship
Insulin Therapies and Hypoglycemia
Save evidence
Evidence topic
Hypoglycemia
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Reduction in HbA1c levels in MASH responders
Insulin aspart → Reduction in HbA1c levels in MASH responders
Insulin aspart → Reduction in HbA1c levels in MASH responders
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerTotal daily insulin dose
Insulin aspart → Total daily insulin dose
Insulin aspart → Total daily insulin dose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerHypoglycemia events
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Hypoglycemia events
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Hypoglycemia events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerReduction in HbA1c levels in MASH responders
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Reduction in HbA1c levels in MASH responders
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Reduction in HbA1c levels in MASH responders
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerTotal daily insulin dose
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Total daily insulin dose
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Total daily insulin dose
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- iGlarLixi reduced HbA1c by -0.59 percentage more than IDegAsp.
- Total insulin daily doses decreased by -3.34 units/day with iGlarLixi.
- Hypoglycaemia events were lower with iGlarLixi compared to IDegAsp.
Who this applies to
- Chinese adults with suboptimally controlled type 2 diabetes.
- Patients requiring insulin therapy for diabetes management.
Keep in Mind
- Results may not be applicable to populations outside of China.
- The study did not establish long-term outcomes or safety.
- Further research is needed to confirm findings in diverse populations.
Between the Lines
- The study's effectiveness data were classified as unclear.
- Limited generalizability due to the specific population studied.
- Potential for unmeasured confounders affecting outcomes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and Insulin Resistance, Insulin aspart and Insulin Resistance.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Insulin Therapies → Insulin Resistance
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceMedications
Insulin aspart → Insulin Resistance
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Insulin Resistance Evidence Hub
All studies measuring Insulin Resistance
3 studies
outcome_hubMeasures Insulin Resistance as a key outcome.
Insulin Therapies Evidence Hub
All studies on Insulin Therapies
3 studies
intervention_hubContributes to Insulin Therapies evidence base.
Insulin aspart Evidence Hub
All studies on Insulin aspart
1 studies
intervention_hubContributes to Insulin aspart evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Total daily insulin dose
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)Outcome: Total daily insulin dose
3 results
All studies on Insulin aspart and Total daily insulin dose
Intervention: Insulin aspartOutcome: Total daily insulin dose
1 results
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
3 results
All studies on Insulin aspart
Intervention: Insulin aspart
1 results
All studies measuring Total daily insulin dose
Outcome: Total daily insulin dose
3 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do Insulin Therapies improve insulin resistance?
Strong Evidence
Insulin Therapies appear to improve insulin resistance.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Total daily insulin dose
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Do Insulin Therapies affect hypoglycemia?
Strong Evidence
Insulin Therapies may affect hypoglycemia.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Does Insulin aspart affect hypoglycemia events?
Emerging Evidence
Insulin aspart appears to affect hypoglycemia events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
What evidence is available on Insulin aspart and reduction in HbA1c levels in mash responders?
Emerging Evidence
Insulin aspart appears to reduce reduction in HbA1c levels in mash responders.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Reduction in HbA1c levels in MASH responders
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
All studies on Insulin aspart and Reduction in HbA1c levels in MASH respondersAll studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Reduction in HbA1c levels in MASH respondersAll studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Total daily insulin doseAll studies on Insulin aspart and Hypoglycemia events
Related research
Read related research summaries.
iDegLira improves glycemic control in type 2 diabetesiGlarLixi improves glycemic control and reduces insulin injections in type 2 diabetesBedtime snacks worsen nighttime blood sugar control in young childrenInsulin dose reductions improve glucose control during exerciseLixisenatide shows no significant effect on arterial stiffness in diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.